BSE · 524717
Titan Biotech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹49 Cr with net profit ₹7 Cr — a 13.43% net margin, versus 13.93% the period before.
Shareholding
As of 2026-06-30
- Promoter55.78%
- Public44.21%
- DII0.01%
18,671 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 6.75× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 4. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 6.75× (₹82.31 to ₹555.65) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #48 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,74,684 Cr | 38.19 | 5.68 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,278 Cr | 214.92 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,12,139 Cr | 20.64 | 4.14 | 18.59% | 18.86% |
| Lupin Limited | ₹1,12,118 Cr | 70.4 | 4.99 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,181 Cr | 193.1 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,251 Cr | 344.6 | 18.15 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,311 Cr | 430.91 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,539 Cr | 100.46 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,966 Cr | 546.39 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,746 Cr | 286.6 | 4.9 | 16.66% | 15.65% |
| Titan Biotech Ltd.(this company) | ₹1,751 Cr | 58.62 | 9.65 | 16.46% | 14.49% |
AI analysis
AI-generated · google/gemini-2.5-flashTitan Biotech Ltd. is listed with a market capitalization of Rs 1772 Cr. The company reported an EPS of 7.23 and a book value of 43.94. As of Mar 2025, annual revenue stood at Rs 160.3633 Cr with a net profit of Rs 21.5316 Cr.
Positives
- +The company has a low debt-to-equity ratio of 0.04.
- +The promoter holding is 55.7801% as of Jun 2026.
- +The company's Return on Capital Employed (ROCE) is 20.8745%.
- +No promoter shares are pledged.
Negatives
- −The company is under LT-ASM surveillance, as indicated by the 'LT-ASM · ASM 4' flag.
- −Quarterly EPS is not disclosed for any quarter across the provided data.
- −Revenue figures for the quarters Dec 2025 (Rs 56.51 Cr) and Mar 2026 (Rs 48.83 Cr) are lower than the annual revenue as of Mar 2025 (Rs 160.3633 Cr).
- −Net profit in the Mar 2026 quarter was Rs 6.73 Cr, which is lower than the Rs 8.53 Cr reported in the Dec 2025 quarter.
Financial Performance
For the fiscal year ending Mar 2025, Titan Biotech Ltd. reported an annual revenue of Rs 160.3633 Cr and a net profit of Rs 21.5316 Cr. The company's EPS for this period was 26.06. In the quarter ending Mar 2026, revenue was Rs 48.83 Cr and net profit was Rs 6.73 Cr.
Profitability & Returns
Titan Biotech Ltd. recorded a profit margin of 14.49%. The company's Return on Equity (ROE) was 16.46% and Return on Capital Employed (ROCE) was 20.8745%. The diluted EPS stands at 7.23.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.04. The book value per share is 43.94. No promoter shares are pledged as of the latest disclosure (Jun 2026).
Ownership & Pledges
As of Jun 2026, promoter holding in Titan Biotech Ltd. was 55.7801%. Public shareholders held 44.2131%, and DIIs/Institutions held 0.0068%. There are no pledged promoter shares.
Regulatory & Surveillance
Titan Biotech Ltd. is currently under LT-ASM (Additional Surveillance Measure) with a label of ASM 4.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.